--- title: "\"Performance\" FOUR SEAS MER's interim net profit of HKD 13.08 million fell by 36%, with a dividend of 3 cents" type: "News" locale: "en" url: "https://longbridge.com/en/news/267955810.md" description: "FOUR SEAS MER announced its interim results for the six months ending in September, with revenue of 1.77 billion yuan, an increase of 3.2% year-on-year. It recorded a net profit of 13.08 million yuan, a decline of 36.1%, with earnings per share of 3.4 cents. The interim dividend remains at 3 cents" datetime: "2025-11-30T08:28:14.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/267955810.md) - [en](https://longbridge.com/en/news/267955810.md) - [zh-HK](https://longbridge.com/zh-HK/news/267955810.md) --- > Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/267955810.md) | [繁體中文](https://longbridge.com/zh-HK/news/267955810.md) # "Performance" FOUR SEAS MER's interim net profit of HKD 13.08 million fell by 36%, with a dividend of 3 cents FOUR SEAS MER (00374.HK) announced its interim results for the six months ending in September, with revenue of HKD 1.77 billion, an increase of 3.2% year-on-year. It recorded a net profit of HKD 13.08 million, a decline of 36.1%, with earnings per share of 3.4 cents. The interim dividend remains at 3 cents ### Related Stocks - [FOUR SEAS MER (00374.HK)](https://longbridge.com/en/quote/00374.HK.md) ## Related News & Research - [A Look At Fosun International (SEHK:656) Valuation After Recent Mixed Share Price Performance](https://longbridge.com/en/news/281035263.md) - [Osl Group FY adjusted non-IFRS income HK$534.1 million](https://longbridge.com/en/news/281223382.md) - [CSPC Pharmaceutical, Alphamab Oncology's Breast Cancer Drug Study Meets Primary Endpoint](https://longbridge.com/en/news/281325910.md) - [Butong Group Expands Share Pool for Award Scheme With On-Market Purchase](https://longbridge.com/en/news/280828310.md) - [CICC Sticks to Its Buy Rating for C&D International Investment Group Ltd. (1908)](https://longbridge.com/en/news/280899096.md)